A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00303563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Study to Compare the Effect of RO4402257 Monotherapy and Methotrexate Monotherapy on Disease Response in Patients With Active Rheumatoid Arthritis.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This 4 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of P38 Inhibitor (4) (50, 150 or 300mg po qd) monotherapy versus methotrexate monotherapy in adult patients with active rheumatoid arthritis. Patients will be randomized to receive one of 3 doses of P38 Inhibitor (4) or methotrexate. The anticipated time on study treatment is \<3 months, and the target sample size is 100-500 individuals.
Study identification
- NCT ID
- NCT00303563
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 204 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2006
- Primary completion
- Nov 30, 2007
- Completion
- Nov 30, 2007
- Last update posted
- Nov 1, 2016
2006 – 2007
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anniston | Alabama | 36207 | — |
| Not listed | Scottsdale | Arizona | 85251 | — |
| Not listed | Tucson | Arizona | 85704 | — |
| Not listed | Tucson | Arizona | 85712 | — |
| Not listed | Escondido | California | 92025 | — |
| Not listed | Loma Linda | California | 92357 | — |
| Not listed | Stamford | Connecticut | 06905 | — |
| Not listed | Morton Grove | Illinois | 60053 | — |
| Not listed | South Bend | Indiana | 46601 | — |
| Not listed | Wichita | Kansas | 67207 | — |
| Not listed | Louisville | Kentucky | 40292 | — |
| Not listed | New Orleans | Louisiana | 70115 | — |
| Not listed | Belmont | North Carolina | 28012 | — |
| Not listed | Bend | Oregon | 97701 | — |
| Not listed | Danville | Pennsylvania | 17822 | — |
| Not listed | Lancaster | Pennsylvania | 17604 | — |
| Not listed | Charleston | South Carolina | 29407 | — |
| Not listed | Knoxville | Tennessee | 37909 | — |
| Not listed | Memphis | Tennessee | 38104 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Amarillo | Texas | 79106 | — |
| Not listed | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00303563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00303563 live on ClinicalTrials.gov.